2024
TRP14 is the rate limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation. EMBO Journal. Accepted 2024. DOI: 10.1038/s44318-024-00117-1
The mitochondrial Na+/Ca2+ exchanger NCLX is implied in the activation of hypoxia-inducible factors. Redox Biol. Nov 2024. DOI: 10.1016/j.redox.2024.103364
The NRF2 inducer CDDO-2P-Im provokes a reduction in amyloid ? levels in Alzheimer’s disease model mice. J Biochem. Sept 2024. DOI: 10.1093/jb/mvae060
Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties. Eur J Med Chem. Aug 2024. DOI: 10.1016/j.ejmech.2024.116763
Biomarkers of NRF2 signalling: Current status and future challenges. Redox Biol. Jun 2024. DOI: 10.1016/j.redox.2024.103134
Inhibition of glycogen synthase kinase-3 enhances NRF2 protein stability, nuclear localisation and target gene transcription in pancreatic beta cells. Redox Biol. May 2024. DOI: 10.1016/j.redox.2024.103117
Innovative pathological network-based multitarget approaches for Alzheimer’s disease treatment. Med Res Rev. Apr 2024. DOI: 10.1002/med.22045
Adipose tissue as a therapeutic target for vascular damage in Alzheimer’s disease. Br J Pharmacol. Mar 2024. DOI: 10.1111/bph.16243
Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH. Redox Biol. Feb 2024. DOI: 10.1016/j.redox.2024.103027
The Melatonin Derivative ITH13001 Prevents Hypertension and Cardiovascular Alterations in Angiotensin II-Infused mice. J Pharmacol Exp Ther. Jan 2024. DOI: 10.1124/jpet.123.001586
2023
Drug repurposing on Alzheimer’s disease through modulation of NRF2 neighborhood. Redox Biol. Nov 2023. DOI: 10.1016/j.redox.2023.102881
Redox regulation of microglial inflammatory response: Fine control of NLRP3 inflammasome through Nrf2 and NOX4. Antioxidants (Basel). Sep 2023. DOI: 10.3390/antiox12091729
Adipose tissue as a therapeutic target for vascular damage in Alzheimer’s disease. Br J Pharmacol. Sep 2023. DOI: 10.1111/bph.16243
Mechanisms of NURR1 regulation: consequences for its biological activity and involvement in pathology. Int J Mol Sci. Jul 2023. DOI: 10.3390/ijms241512280
Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets. Redox Biol. Apr 2023. DOI: 10.1016/j.redox.2023.102603
The transcription factor NRF2 has epigenetic regulatory functions modulating HDACs, DNMTs, and miRNA biogenesis. Antioxidants. Mar 2023. DOI: 10.3390/antiox12030641
8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin’s antidepressant profile: synthesis, biological evaluation and docking studies. Eur. J. Med. Chem. Feb 2023. DOI: 10.1016/j.ejmech.2023.115091
Introduction to special issue on «Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases». Free Radic Biol Med. Feb 2023. DOI: 10.1016/j.freeradbiomed.2022.12.100
Small synthetic hyaluronan disaccharide BIS014 mitigates neuropathic pain in mice. J Pain. Jan 2023. DOI: 10.1016/j.jpain.2022.07.014
Cytotoxicity models in chromaffin cells to evaluate neuroprotective compounds. Methods Mol Biol. 2023. DOI:https://pubmed.ncbi.nlm.nih.gov/36205906/https://doi.org/10.1002/med.21925
2022
Impairment in novelty-promoted memory via behavioral tagging and capture before apparent memory loss in a knock-in model of Alzheimer’s disease. Sci Rep. Dec 2022. DOI: 10.1038/s41598-022-26113-1
The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance. Free Radic Biol Med. Nov 2022. DOI: 10.1016/j.freeradbiomed.2022.09.023
Overlooked and valuable facts to know in the NRF2/KEAP1 field. Free Radic Biol Med. Nov 2022. DOI: 10.1016/j.freeradbiomed.2022.08.044
Microglial Hemoxygenase-1 deletion reduces inflammation in the retina of old mice with tauopathy. Antioxidants (Basel). Oct 2022. DOI: 10.3390/antiox11112151
Dipeptide repeat pathology in c9orf72-ALS is associated with redox, mitochondrial and NRF2 pathway imbalance. Antioxidants (Basel). Sep 2022. DOI: 10.3390/antiox11101897
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. J Med Chem. Oct 2022. DOI:10.1021/acs.jmedchem.2c00515
Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis. Free Radic Biol Med. Sep 2022. DOI: 10.1016/j.freeradbiomed.2022.08.012
An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter β-TrCP delivers anti-inflammatory responses in mouse liver. Redox Biol. Sep 2022. DOI: 10.1016/j.redox.2022.102396
KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential. Medicinal Research Reviews. Sep 2022. DOI:https://doi.org/10.1002/med.21925
Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. Free Radic Biol Med. Jul 2022. DOI: 10.1016/j.freeradbiomed.2022.05.016
Loss of KEAP1 causes an accumulation of nondegradative organelles. Antioxidants (Basel). Jul 2022. DOI: 10.3390/antiox11071398
Brain-protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2022. DOI: http://10.1146/annurev-pharmtox-052220-103416
Antinociceptive and modulatory effect of pathoplastic changes in spinal glia of a TLR4 /CD14 blocking molecule in two models of pain in rat. Biomed Pharmacother. Jun 2022. DOI: 10.1016/j.biopha.2022.112986
Transcription factor NRF2 participates in cell cycle progression at the level of G1/S and mitotic checkpoints. Antioxidants. May 2022. DOI: http://10.3390/antiox11050946
Novel series of dual NRF2 inducers and selective MAO-B inhibitors for the treatment of Parkinson’s disease. Antioxidants. Feb 2022. DOI: http://10.3390/antiox11020247
Implication of type 4 NADPH oxidase (NOX4) in tauopathy. Redox Biology. Feb 2022. DOI: 10.1016/j.redox.2021.102210
Antinociceptive and modulatory effect of pathoplastic changes in spinal glia of a TLR4/CD14 blocking molecule in two models of pain in rat. Biomed. Pharmacother. 2022. DOI: https://doi.org/10.1016/j.biopha.2022.112986
Resveratrol-based MTDLs to stimulate defensive and regenerative pathways and block early events in neurodegenerative cascades. J. Med. Chem. 2022. DOI: https://doi.org/10.1021/acs.jmedchem.1c01883
Curcumin-piperlongumine hybrids with a multitarget profile elicit neuroprotection in in vitro models of oxidative stress and hyperphosphorylation. Antioxidants. Jan 2022. DOI: http://10.3390/antiox11010028
Enantioselective synthesis and pharmacological evaluation of AZA-CGP37157-Lipoic Acid hybrids for the treatment of Alzheimer’s disease. Antioxidants (Basel). Jan 2022. DOI: 10.3390/antiox11010112
2021
Central Activation of Alpha7 Nicotinic Signaling Attenuates LPS-Induced Neuroinflammation and Sickness Behavior in Adult but Not in Aged Animals. Molecules. Apr. 2021. DOI: 10.3390/molecules26082107
Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nature Communcations. Dec 2021. DOI:http://10.1038/s41467-021-22501-9
Bisavenathramide analogues as nrf2 inductors and neuroprotectors in in vitro models of oxidative stress and hyperphosphorylation. Antioxidants. Jun 2021. DOI: http://10.3390/antiox10060941
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathol Commun. May 2021. DOI: http://10.1186/s40478-021-01196-5
NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radical Biology and Medicine. Sep 2021. DOI: http://10.1016/j.freeradbiomed.2021.07.022
Intracellular calcium and inflammatory markers, mediated by purinergic stimulation, are differentially regulated in monocytes of patients with major depressive disorder. Neuroscience Letters. Nov 2021. DOI:http://10.1016/j.neulet.2021.136275
Enhanced stability and bioactivity of natural anticancer topoisomerase i inhibitors through cyclodextrin complexation. Pharmaceutics. Oct 2021. DOI: http://10.3390/pharmaceutics13101609
α-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. Molecular Neurobiology. Dec 2021. DOI: http://10.1007/s12035-021-02558-9
Synthesis and in vitro study of nitro- and methoxy-2-phenylbenzofurans as human monoamine oxidase inhibitors. Bioorg. Chem. 2021. DOI: https://doi.org/10.1016/j.bioorg.2020.104616.
Protective role of microglial HO-1 blockade in aging: implication of iron metabolism. Redox Biology. Jan 2021. DOI: 10.1016/j.redox.2020.101789.
2020
Cognitive enhancement, tau phosphorylation reduction and neuronal protection by the treatment of a LRRK2 inhibitor in a taoupathy mouse model. Neurobiology of Aging. Dec 2020. DOI: 10.1016/j.neurobiolaging.2020.09.006
Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research. Feb 2020. DOI: 10.1016/j.phrs.2019.104597
Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases. Frontiers in Pharmacology. Feb 2020. DOI: http://10.3389/fphar.2020.00151
Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. Eur. J. Med. Chem. Mar 2020. DOI: 10.1016/j.ejmech.2020.112090
Optical control of muscular nicotinic channels with azocuroniums, photoswitchable azobenzenes bearing two N-methyl-N-carbocyclic quaternary ammonium groups. Eur. J. Med. Chem. May 2020. DOI: 10.1016/j.ejmech.2020.112403
Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties. Drug Development Research. May 2020. DOI: 10.1002/ddr.21618
NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. Jun 2020. DOI: 10.3390/biom10060904
Aging and Progression of Beta-Amyloid Pathology in Alzheimer’s Disease Correlates with Microglial Heme-Oxygenase-1 Overexpression. Antioxidants. Jul 2020. DOI: 10.3390/antiox9070644
Na+ controls hypoxic signalling by the mitochondrial respiratory chain. Nature. Jul 2020. DOI 10.1038/s41586-020-2551-y.
Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease. Antioxidants. Aug 2020. DOI:
When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. Antioxidants. Aug 2020. DOI: 10.3390/antiox9080740
Protective role of microglial HO-1 blockade in aging: Implication of iron metabolism. Redox Biology. Nov 2020. DOI: 10.1016/j.redox.2020.101789
Wip modulates oxidative stress through NRF2/KEAP1 in glioblastoma cells. Antioxidants. Sep. 2020. DOI: http://10.3390/antiox9090773
Can Activation of NRF2 Be a Strategy against COVID-19?Antioxidants. Trends in Pharmacological Sciences. Sep. 2020. DOI: 10.1016/j.tips.2020.07.003
Perspectives on the Clinical Development of NRF2-Targeting Drugs. Handbook of Experimental Pharmacology (Chapter). Aug 2020. DOI: 10.1007/164_2020_381
New Nrf2-inducer compound ITH12674 slows the progression of retinitis pigmentosa in the mouse model rd10. Cellular Physiology And Biochemistry. 2020. DOI: http://10.33594/000000210
2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. Jan 2019. DOI: 10.1038/s41573-018-0008-
New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. J. Enzyme Inhib. Med. Chem. Mar 2019. DOI: 10.1080/14756366.2019.1581184
Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. Jul 2019. DOI: 10.1155/2019/9372182
Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux. Journal of Pineal research. Aug 2019. DOI: http://10.1111/jpi.12578
2018
Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. Apr 2018. DOI: 10.1016/j.redox.2017.10.010.
Neurogenic and neuroprotective donepezil-flavonoid hybrids wit sigma-1 affinity and inhibition of key enzymes in Alzheimer’s disease. Eur. J. Med. Chem. 2018. DOI: https://doi.org/10.1016/j.ejmech.2018.07.026.
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. April 2018. DOI:10.1124/pr.117.014753
Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy. Jul 2018. DOI: 10.1080/15548627.2018.1474992
Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol. Sep 2018. DOI: 10.1016/j.redox.2018.07.006
Multi-target-directed ligands for Alzheimer´s disease: discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. Eur. J. Med. Chem. Oct 2018. DOI: 10.1016/j.ejmech.2018.07.056
